2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P5903
    FGF acidic I (102-111) (bovine brain) 198542-00-6 98%
    FGF acidic I (102-111) (bovine brain) (aFGF (102-111)) is the 102-111 fragment of acidic FGF that can be used as a potential neurotrophic agent.
    FGF acidic I (102-111) (bovine brain)
  • HY-P5906
    Citrullinated amyloid-β (1-40) peptide (human) 98%
    Citrullinated amyloid-β (1-40) peptide (human) (Citrullinated Aβ (1-40)) is a modified form of β-Amyloid (1-40) (HY-P0265) with a citrullination at the Arg5 site. Citrullinated amyloid-β (1-40) peptide (human) exhibits increased transient formation of soluble oligomers and insoluble aggregates composed of distorted parallel β-sheets compared with unmodified β-Amyloid (1-40).
    Citrullinated amyloid-β (1-40) peptide (human)
  • HY-P5907
    Helianorphin-19 2883653-86-7 98%
    Helianorphin-19 is a potent and selective κ-opioid receptor (KOR) activator with a Ki of 21 nM and an EC50 of 45 nM. Helianorphin-19 exhibits strong KOR-specific peripheral analgesic activity in a mouse model of chronic visceral pain.
    Helianorphin-19
  • HY-P5916
    VSTx-3 98%
    VSTx-3 is a KV channel blocker. VSTx-3 is demonstrated to be a potent, TTX-sensitive sodium channel blocker and especially, a potent blocker of NaV1.8 channels (IC50 0.19 μM for hNaV1.3, 0.43 μM for hNaV1.7 and 0.77 μM for hNaV1.8 channels).
    VSTx-3
  • HY-P5918
    Galanin-B2 944087-28-9 98%
    Galanin-B2 (NAX-5055) has activity in the epilepsy model. Galanin-B2 can penetrate the blood-brain-barrier.
    Galanin-B2
  • HY-P5920
    Urotoxin 98%
    Urotoxin is an inhibitor of the potassium channel. Urotoxin has a selective affinity for hKv1.2 channel.
    Urotoxin
  • HY-P5921
    Tityustoxin-Kα 152618-71-8 98%
    Tityustoxin-Kα (TsTx-Kα) is an inhibitor of potassium voltage-gated channels. Tityustoxin-Kα shows a dose-dependent block of the sustained outward current in cultured hippocampal neurons .
    Tityustoxin-Kα
  • HY-P5925
    Ssm spooky toxin 98%
    Ssm Spooky Toxin is found in Scolopendra mutilans that potently inhibits KCNQ (voltage-gated potassium channel family 7) channels, with IC50s of 2.8 μM, 5.26 μM and 0.1-0.3 M for Kv7.4, Kv1.3, and Shal channel, respectivily. Ssm Spooky Toxin inhibits cytokine generation by specifically acting on the KV1.3 channel in T cells. Ssm Spooky Toxin plays an essential role in the centipede’s circulatory system .
    Ssm spooky toxin
  • HY-P5940
    β-Amyloid precursor protein (96-110), cyclized (human) 289634-54-4 98%
    β-Amyloid precursor protein (96-110), cyclized (human) is an amyloid precursor protein. β-Amyloid precursor protein (96-110), cyclized (human) can be used in study Alzheimer’s disease.
    β-Amyloid precursor protein (96-110), cyclized (human)
  • HY-P5943
    Pterinotoxin-1 98%
    Pterinotoxin-1 is a sodium channel inhibitor peptide toxin.
    Pterinotoxin-1
  • HY-P5947
    Tat-HA-NR2B9c 98%
    Tat-HA-NR2B9 contains a fragment of the cellmembrane transduction domain of HIV-1 Tat, a influenza virus hemagglutinin (HA) epitope-tag, and the C-terminal 9 amino acids of NR2B (NR2B9c). Tat-HA-NR2B9 reduces infarct size and improves neurological functions in ischemia-induced cerebral injury in the rats
    Tat-HA-NR2B9c
  • HY-P5964
    K1 peptide 2973365-72-7 98%
    K1 peptide is a high-affinity peptide ligand for GABAA receptor-associated protein (GABARAP).
    K1 peptide
  • HY-P5987
    Calmodulin Kinase IINtide, Myristoylated 98%
    Calmodulin Kinase IINtide, Myristoylated (Myr-CaMKIINtide) is a selective and noncompetitive inhibitor of CaMKII.
    Calmodulin Kinase IINtide, Myristoylated
  • HY-P6053
    KK-103 2775287-98-2 98%
    KK-103 is a precursor of leucine-enkephalin (Leu-ENK) overcomes high proteolytic instability of Leu-ENK via markedly increased plasma stability in mice that has antinociceptive effect.
    KK-103
  • HY-P6079
    Ac-IHIHIYI-NH2 2156606-61-8 98%
    Ac-IHIHIYI-NH2 is a fibrous heptapeptide that forms fibril-like structures with even higher esterase activity.
    Ac-IHIHIYI-NH2
  • HY-P6292
    KS-133 2724212-01-3 98%
    KS-133 is a selective and potent antagonist of vasoactive intestinal peptide receptor 2 (VIPR2), with the IC50 values of 24.8 nM and 500 nM in Ca influx assay and cAMP assay. KS-133 plays an important role in schizophrenia research.
    KS-133
  • HY-P6437
    Drp1 peptide inhibitor P110 2770267-63-3 98%
    Drp1 peptide inhibitor P110 (Compound P110) is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 can inhibit the activation of Drp1, prevent MPTP-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction.
    Drp1 peptide inhibitor P110
  • HY-P7060
    NT 13 117928-93-5
    NT 13 (TPPT) is a tetrapeptide having the amino acid sequence L-threonyl-L-prolyl-L-prolyl-L-threonine amide. NT 13 is a partial N-methyl-D-aspartate receptor (NMDAR) agonist used in the study of depression, anxiety, and other related diseases.
    NT 13
  • HY-Y0785
    Glyoxal 107-22-2 98%
    Glyoxal is a cytotoxic α-oxoaldehyde. Glyoxal induces cell damage and promotes protein glycation to form advanced glycation end-products (AGEs). Glyoxal is promising for research of oxidative stress-related diseases (such as atherosclerosis, cataract, Alzheimer's disease), and the formation of calcium oxalate kidney stones.
    Glyoxal
  • HY-Z4690
    Zolmitriptan N-Oxide 251451-30-6 98%
    Zolmitriptan N-Oxide is the major metabolite of Zolmitriptan. Zolmitriptan is a 5-HT1B/1D receptor partial agonist.
    Zolmitriptan N-Oxide
Cat. No. Product Name / Synonyms Application Reactivity